Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Evotec Expands Sanofi Link With Exclusive Stem Cell Diabetes Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Evotec’s deal with the French drugmaker to develop stem cell-based treatments for diabetes takes on even more importance following the demise of the biotech’s two lead proprietary candidate therapies.


Related Content

Deal Watch: Biogen Picks Up S1P Modulator To Try Competing With Novartis, Celgene
Deal Watch: Immuno-Oncology Collaborations Keep Piling Up
Evotec CEO: Growth Prospects Rely Heavily On Roche, Sanofi Deals
Evotec Drug Development Strategy Offers Little Downside, Big Upside
Deals Of The Week: Mylan/Bioniche; Watson/Itero; Genentech/MRC Technology...


Related Companies

Related Deals